HC Wainwright Reiterates Buy Rating for Inventiva (NASDAQ:IVA)

Inventiva (NASDAQ:IVA)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $13.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 428.24% from the company’s previous close.

Several other research firms have also recently issued reports on IVA. UBS Group assumed coverage on Inventiva in a report on Tuesday, November 12th. They issued a “neutral” rating and a $3.00 price objective on the stock. Stifel Nicolaus reduced their price target on Inventiva from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, November 22nd.

Inventiva Trading Up 1.7 %

IVA opened at $2.46 on Thursday. Inventiva has a 1 year low of $1.53 and a 1 year high of $4.50. The firm has a fifty day moving average price of $2.36 and a 200 day moving average price of $2.35.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.